Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook for 2025.
In the three months ending December 31, Eli Lilly's revenue increased 44.7% year over year to $13.5 billion, driven by demand for its weight-loss drugs, Mounjaro and Zepbound. Earnings per share (EPS) rose 113.7% from the year-ago period to $5.32.
"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in treating chronic disease associated with obesity."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Eli Lilly also "invested billions more" in its manufacturing capacity and launched Kisunla and Ebglyss. The latter will be "important drivers of our long-term balanced growth outlook," Ricks said. Kisunla is designed to treat early stage Alzheimer's disease, while Ebglyss is for eczema.
The results were mixed compared with analysts' expectations. Wall Street was anticipating revenue of $13.5 billion and earnings of $5.01 per share, according to MarketWatch.
For 2025, Eli Lilly expects to achieve revenue in the range of $58 billion to $61 billion and earnings of $22.50 to $24 per share. The midpoints of these ranges, revenue of $59.5 billion and earnings of $23.25 per share, came in ahead of analysts' expectations of revenue of $58.8 billion and earnings of $22.76 per share.
"We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth," Ricks said.
That should support the drug maker's quarterly payout to shareholders as well. Eli Lilly's long track record makes it one of Wall Street's best dividend stock.
Competition in the weight-loss drug category with Novo Nordisk (NVO) and its Ozempic continues to define Eli Lilly's results. A recent Food and Drug Administration clarification of the tirzepatide shortage should help both LLY and NVO.
Is Eli Lilly stock a buy, sell or hold?
LLY tumbled 6.6% on January 14 after management pre-announced fourth-quarter results. Sales for Mounjaro and Zepbound met expectations set in mid-January, and Wall Street sees further upside for the healthcare stock.
According to S&P Global Market Intelligence, the consensus analyst target price for LLY stock is $975.09, representing implied upside of about 14% to current levels. And the consensus recommendation is Buy.
Financial services firm Jefferies has a Buy rating on the large-cap stock with a $994 price target.
"We're bullish on LLY for several reasons," Jefferies analyst Akash Tewari said in a December 19 note, citing Eli Lilly's attractive growth profile in a recessionary environment and the potential for GLP-1s to be among the biggest drug classes of all time.
The analyst also sees near-term upside for both revenue and EPS growth.
Related Content
-
Trump's Immigration Policies and the Price of Home Healthcare: First 100 DaysPresident Trump's immigration policies may wallop your pocketbook if you rely on a home healthcare aide.
-
Stock Market Today: Stocks Extend a Quiet Winning StreakThe S&P 500 Index could actually close April with a monthly gain, which would be an extraordinary sign of market resilience.
-
Stock Market Today: Stocks Extend a Quiet Winning Streak
The S&P 500 Index could actually close April with a monthly gain, which would be an extraordinary sign of market resilience.
-
How Trump's First 100 Days Have Impacted Your PortfolioPresident Trump's first 100 days in office have been busy, with a flurry of executive orders sparking volatility in the stock and bond markets.
-
Is It Still Worth It to Gift Savings Bonds?Kiplinger editor explores if it's still a good idea to get savings bonds as gifts for children, looking at their returns and usability.
-
Don't Veer Off Course at the First Sign of a Squall in the MarketsWhen markets go nuts and investor sentiment drops, you can keep your sanity by trusting in and sticking with your long-term plan.
-
How Business Owners Can Prepare for a Terminal DiagnosisThe most important thing is readiness, whether the owner faces a life-changing diagnosis or an employee does.
-
Advisers, Take Note: How 2025 Social Security Changes May Impact Your ClientsWhat financial advisers might need to know to help their clients navigate Social Security in 2025.
-
Stock Market Today: Have We Seen the Bottom for Stocks?Solid first-quarter earnings suggest fundamentals remain solid, and recent price action is encouraging too.
-
Social Security Is Taxable, But There Are WorkaroundsIf you're strategic about your retirement account withdrawals, you can potentially minimize the taxes you'll pay on your Social Security benefits.
